Table 2. Univariable and multivariable Cox regression analysis of the lncRNA signature and overall survival in the training cohort (n=113), in the validation cohort (n=112) and in the combined cohort (n=225).

Variables	Univariable analysis		Multivariable analysis
	HR (95% CI)	P value	HR (95% CI)	P value
Training cohort (n=113)
LncRNA signature	2.718 (1.916-3.857)	<0.001	3.518 (2.331-5.310)	<0.001
Age	1.021 (1.004-1.039)	0.019	1.011 (0.992-1.031)	0.253
Gender(male/female)	1.214 (0.729-2.023)	0.458	1.259 (0.705-2.249)	0.437
Stage II	1.889 (0.881-4.053)	0.102	1.864 (0.861-4.039)	0.114
Stage III	2.412 (1.214-4.792)	0.012	2.214 (1.098-4.467)	0.026
Stage IV	4.677 (0.584-37.467)	0.146	21.13 (2.274-196.386)	0.007
Testing cohort (n=112)
LncRNA signature	1.434 (1.091-1.885)	0.01	1.62 (1.178-2.231)	0.003
Age	1.027 (1.009-1.044)	0.002	1.02 (1.004-1.042)	0.018
Gender(male/female)	1.237 (0.745-2.056)	0.411	1.17 (0.658-2.069)	0.599
Stage II	1.3297 (0.646-2.737)	0.439	1.00(0.472-2.133)	0.993
Stage III	1.443 (0.737-2.824)	0.285	1.61 (0.805-3.234)	0.178
Stage IV	2.168 (0.775-6.063)	0.14	2.43 (0.853-6.943)	0.096
Combined cohort (n=225)
LncRNA signature	1.794 (1.453-2.216)	<0.001	2.043 (1.616-2.583)	<0.001
Age	1.024 (1.012-1.036)	<0.001	1.017 (1.003-1.03)	0.014
Gender(male/female)	1.230 (0.868-1.769)	0.237	1.219 (0.817-1.819)	0.333
Stage II	1.522 (0.912-2.540)	0.108	1.188(0.693-2.038)	0.531
Stage III	1.786 (1.118-2.854)	0.015	1.926 (1.196-3.102)	0.007
Stage IV	2.672 (1.096-6.513)	0.031	3.21 (1.298-7.941)	0.012